Aminolevulinic acid and Apo-Sulfatrim
Determining the interaction of Aminolevulinic acid and Apo-Sulfatrim and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid. MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible. Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid. References "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.
Professional:GENERALLY AVOID: Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.
MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible. Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid.
- "Product Information. Gleolan (aminolevulinic acid)." NX Development Corp, Lexington, KY.
Generic Name: aminolevulinic acid
Brand name: Gleolan
Synonyms: n.a.
Generic Name: sulfamethoxazole / trimethoprim
Brand name: Bactrim, Bactrim DS, Bactrim IV, Septra IV, SMZ-TMP DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS
Synonyms: Sulfamethoxazole and trimethoprim, Sulfamethoxazole and Trimethoprim
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aminolevulinic acid-Apokyn
- Aminolevulinic acid-Apomorphine
- Aminolevulinic acid-Apomorphine Ampules
- Aminolevulinic acid-Apomorphine Cartridges and Pens
- Aminolevulinic acid-Apomorphine Hydrochloride
- Aminolevulinic acid-Apomorphine Subcutaneous
- Apo-Sulfatrim-Aminolevulinic Acid (Systemic)
- Apo-Sulfatrim-Aminolevulinic Acid Gel
- Apo-Sulfatrim-Aminolevulinic Acid Hydrochloride
- Apo-Sulfatrim-Aminolevulinic Acid Solution
- Apo-Sulfatrim-Aminolevulinic acid topical
- Apo-Sulfatrim-Aminomine